



## Preclinical Data Highlighting ADXS-Hot as Immunotherapy with Potential to Target Hotspot Cancer Mutations across Multiple Cancer Types Presented in Poster Discussion at The AACR Annual Meeting

April 17, 2018

### ***Lm* platform targets common mutations in tumor driver genes**

PRINCETON, N.J.--(BUSINESS WIRE)-- [Advaxis, Inc.](#) (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces the presentation of ADXS-HOT preclinical data in a poster discussion entitled "*Targeting Shared Hotspot Cancer Mutations with a Listeria monocytogenes Immunotherapy Induce Potent Anti-Tumor Immunity*" at the American Association for Cancer Research (AACR) Annual Meeting underway in Chicago. The discussion, held yesterday, was led by Daniel O. Villarreal, Ph.D., Principal Scientist at Advaxis. The ADXS-HOT franchise leverages the Company's proprietary *Lm* Technology to target common mutations in tumor driver genes.

---

**"Targeting Shared Hotspot Cancer Mutations with a *Listeria monocytogenes* Immunotherapy Induce Potent Anti-Tumor Immunity"**

---

This study's objective was to identify and target common (public or shared) mutations (hotspots) and to determine if the ADXS-HOT platform could effectively target those hotspots and control tumor growth. Results indicate that ADXS-HOT could achieve this in preclinical models against single and multi-target constructs. The full abstract is available here: <https://www.advaxis.com/wp-content/uploads/2018/04/HOT-AACR-Abstract-Final-2018.pdf>

"The results of this preclinical work with ADXS-HOT represent an exciting opportunity that may allow us to develop disease-specific immunotherapies that have the potential to be effective against multiple targets, capable of generating high-avidity T cells against shared or public mutations, as well as multiple proprietary highly immunogenic cancer-testes and oncofetal antigens for multiple tumor types," said Robert G. Petit, Ph.D., Executive Vice President and Chief Scientific Officer of Advaxis. "Additionally, the results show increased functionality and resiliency in CD8 T cells upon restimulation, indicating the potential not only to increase the number and frequency of CD8 T cells, but to strengthen them."

### **About ADXS-HOT**

ADXS-HOT leverages the Company's proprietary *Lm* technology to target common "hotspot" mutations. ADXS-HOT products are designed to target acquired shared or "public" mutations in tumor driver genes along with cancer-testes and oncofetal tumor-associated antigens that are shared by multiple patients. Although ADXS-HOT has not been tested in patients, in theory, products would be designed to treat all patients with a particular type of cancer, without the need for pre-treatment testing, biopsy, DNA sequencing or diagnostic testing.

### **About Advaxis, Inc.**

Advaxis, Inc. is a late-stage biotechnology company focused on the discovery, development and commercialization of proprietary *Lm*-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated *Listeria monocytogenes* (*Lm*) bioengineered to secrete antigen/adjuvant fusion proteins. These *Lm*-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T cells to eliminate tumors. Advaxis has four franchises in various stages of clinical and preclinical development: HPV-associated cancers, neoantigen therapy, hotspot cancer antigens and prostate cancer.

To learn more about Advaxis, visit [www.advaxis.com](http://www.advaxis.com) and connect on Twitter, LinkedIn, Facebook, and YouTube.

### **Advaxis Forward-Looking Statement**

This press release contains forward-looking statements, including, but not limited to, statements regarding Advaxis' ability to develop and commercialize the next generation of cancer immunotherapies, and the safety and efficacy of Advaxis' proprietary immunotherapies. These forward-looking statements are subject to a number of risks including the risk factors set forth from time to time in Advaxis' SEC filings including, but not limited to, its report on Form 10-K for the fiscal year ended October 31, 2017, and on Form 10-Q for the quarter ended January 31, 2018, which are available at [www.sec.gov](http://www.sec.gov).

Any forward-looking statements set forth in this presentation speak only as of the date of this presentation. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof other than as required by law. You are cautioned not to place undue reliance on any forward-looking statements.

### **CONTACT:**

Company:  
[Advaxis, Inc.](#)  
Noelle Heber, 609-250-7575

Sr. Director Corporate Communications and Government Affairs  
[Heber@advaxis.com](mailto:Heber@advaxis.com)

or

Investors:

[LHA Investor Relations](#)

Miriam Weber Miller, 212-838-3777

[mmiller@lhai.com](mailto:mmiller@lhai.com)